Back to search results

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Abroad (travel likely)RecruitingPHASE2

Conditions

Thyroid Cancer · Cancer of the Thyroid

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Brendan Knapp, M.D.) · bjknapp@wustl.edu · 314-362-5485
    Contact: Principal Investigator (Brendan Knapp, M.D.)
    Douglas Adkins, M.D. (Sub-investigator)
    Jesse Zaretsky, M.D., Ph.D. (Sub-investigator)
    Christine Auberle, M.D. (Sub-investigator)
    Peter Oppelt, M.D. (Sub-investigator)
    Sina Jasim, M.D. (Sub-investigator)
    Esther Lu, Ph.D. (Sub-investigator)
Study leads

  • Brendan Knapp, M.D.

    Principal Investigator

    Washington University School of Medicine

View source on ClinicalTrials.gov(opens in a new tab)